| Founded | 2000 |
|---|---|
| Closed | 2016 |
| Country | USA |
| Sector | Biotech |
| Collapse type | Slow Death |
Synta Pharmaceuticals
"The HSP90 inhibitor biotech that failed its Phase 3 lung cancer trial and reverse-merged into Madrigal Pharmaceuticals."
Years-long decline before final shutdown
Key Events Timeline
Synta spent 16 years developing ganetespib, an HSP90 inhibitor for non-small cell lung cancer.
// full analysis
Full analysis requires the Analyst plan
Documented cause · Market cycle · Competitive moat type · Verified lesson
€149/mo · or contribute your autopsy for free access →
UnicornBurn Season 0 opens July 2026. 10,000 founders competing in one world. Your startup fights for the market every Saturday. Most will end up here. Which one are you?
JOIN SEASON 0 →Synta Pharmaceuticals followed a documented pattern. Identify the same signals in any company before they reach the point of no return.
Witnessed a startup failure first-hand? Share the real story. First-hand accounts from founders and team members get prioritized for publication.
SUBMIT AN AUTOPSY →Failure intelligence for due diligence and risk analysis.
Structured dataset by collapse type, for 5031 startups. 7-day trial.
See plans →Free JSON API. No key required. 50 autopsies, 10 req/day.
Full dataset available with Intelligence plan API key. CORS enabled.
Explore API →Academic, press, or research use? Free JSON API available — no auth required →